Niraparib Shows Favorable Outcomes in Germline BRCA+ Recurrent Ovarian Cancer

Video

An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.

A population of patients with germline BRCA-mutated (gBRCA) recurrent ovarian cancer derived overall survival (OS) benefit from niraparib compared with placebo, according to Ursula A. Matulonis, MD.

Matulonis, chief of the Division of Gynecologic Oncology, Brock-Wilson Family Chair, and institute physician at Dana-Farber Cancer Institute and professor of Medicine at Harvard Medical School, spoke with CancerNetwork® at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer regarding the final OS analysis of the phase 3 ENGOT-OV16/NOVA trial (NCT01847274).

The median OS in the gBRCA cohort following treatment with niraparib and placebo, respectively, was 40.9 months vs 38.1 months (HR, 0.85; 95% CI, 0.61-1.20). In the non-gBRCA cohort, the median OS was 31.0 months vs 34.8 months with niraparib and placebo, respectively (HR, 1.06; 95% CI, 0.81-1.37).

Transcript:

[I presented] the original OS data for NOVA in 2021 at the Society of Gynecologic Oncology Annual Meeting. At that point, about 17% [of patients had] missing data for [OS]. The FDA actually strongly recommended that survival status be obtained for as many patients as possible.

[With] these newest OS data—the final OS analysis—98% of patients have known [OS] status, so that missing data of 17% went down to about 2%. What I presented is that for patients with a gBRCA mutated status, the hazard ratio is 0.85 in favor of niraparib vs placebo. The OS is about 41 months for patients [in the] gBRCA [population] receiving niraparib vs about 38 months for patients receiving placebo. It's important that the OS was a secondary end point and not powered for.

In the non-gBRCA patient population, the hazard ratio is 1.06 in favor of placebo. Patients in that group receiving placebo had an OS of about 41 months, and for patients who received niraparib, it was just around 38 months or so.

Reference

Matulonis UA, Herrstedt J, Mahner S, et al. Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer. Presented at Society of Gynecological Oncology 2023 Virtual Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, FL.

Related Videos
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
The use of novel agents like tarlatamab may be “interesting” among patients with small cell lung cancer in the relapsed setting, says Gregory Peter Kalemkerian, MD.
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.
Related Content